Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer-Reference-Cited by-同舟云学术

Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer

Published:2015-01 Issue:2 Volume:51 Page:218-224
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Vassal Gilles,Rousseau Raphaël,Blanc Patricia^ORCID,Moreno Lucas^ORCID,Bode Gerlind,Schwoch Stefan,Schrappe Martin,Skolnik Jeffrey^ORCID,Bergman Lothar,Bradley-Garelik Mary Brigid,Saha Vaskar,Pearson Andy,Zwierzina Heinz

Funder

Cancer Research UK Life Chair and Programme Grant

NIHR RM/ICR Biomedical Research Centre

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Challenges for children and adolescents with cancer in Europe: The SIOP-Europe agenda;Vassal;Pediatr Blood Cancer,2014

2. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries;Pritchard-Jones;Lancet Oncol,2013

3. Children with cancer: driving the global agenda;Pritchard-Jones;Lancet Oncol,2013

4. Childhood cancer survival in Europe: action is needed;Gatta;Epidemiol Prev,2013

5. Long-term cause-specific mortality among survivors of childhood cancer;Reulen;JAMA,2010

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia;Cancers;2023-12-22

2. Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development;JNCI: Journal of the National Cancer Institute;2023-11-17

3. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer – An ACCELERATE Multistakeholder Consensus;Clinical Pharmacology & Therapeutics;2023-11-14

4. A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?;Cancer Treatment Reviews;2023-11

5. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration;European Journal of Cancer;2023-09